Limited evidence for the use of imaging to detect prostate cancer: A systematic review

European Journal of Radiology

Volumn 83, Issue 9, 2014, Pages 1601-1606

  Blomqvist, L ^a,b   Carlsson, S ^a,b   Gjertsson, P ^c   Heintz, E ^f   Hultcrantz, M ^f   Mejare, I ^f   Andren O ^d,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d ÖREBRO UNIVERSITY   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f Swedish Council on Health Technology Assessment   (Sweden)

Author keywords

Biopsy; Diagnosis; Imaging; Meta analysis; Prostate cancer; Systematic review

Indexed keywords

CANCER DIAGNOSIS; CANCER RISK; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPPLER FLOWMETRY; EMBASE; HIGH RISK PATIENT; HUMAN; MEDLINE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TRANSRECTAL ULTRASONOGRAPHY; ADULT; AGED; BIOPSY; DIAGNOSTIC USE; ENDOSCOPIC ECHOGRAPHY; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY; VERY ELDERLY;

CONTRAST MEDIUM;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84906322835     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2014.06.028     Document Type: Review

References (18)

1. F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, and V. Nelen et al. Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
2. T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, and E. Redwine Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916
3. B. Djavan, V. Ravery, A. Zlotta, P. Dobronski, M. Dobrovits, and M. Fakhari et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679 1683
4. R. Raaijmakers, W.J. Kirkels, M.J. Roobol, M.F. Wildhagen, and F.H. Schrder Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program Urology 60 2002 826 830
5. M.J.A. Garcia, E.M. Ward, M.M. Center, Y. Hao, R.L. Siegel, and M.J. Thun Global cancer facts & figures 2007 American Cancer Society Atlanta, GA
6. R. Luengo-Fernandez, J. Leal, A. Gray, and R. Sullivan Economic burden of cancer across the European Union: a population-based cost analysis Lancet Oncol 14 2013 1165 1174
7. L. Dickinson, H.U. Ahmed, C. Allen, J.O. Barentsz, B. Carey, and J.J. Futterer et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting Eur Urol 59 2011 477 494
8. J.O. Barentsz, J. Richenberg, R. Clements, P. Choyke, S. Verma, and G. Villeirs et al. ESUR prostate MR guidelines 2012 Eur Radiol 22 2012 746 757
9. P. Whiting, A.W. Rutjes, J.B. Reitsma, P.M. Bossuyt, and J. Kleijnen The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Med Res Methodol 3 2003 25
10. Assessment SCoHT Evaluation and synthesis of methods in healthcare: a handbook 2013 SBU Stockholm, Sweden
11. H. Balshem, M. Helfand, H.J. Schunemann, A.D. Oxman, R. Kunz, and J. Brozek et al. GRADE guidelines: 3. Rating the quality of evidence J Clin Epidemiol 64 2011 401 406
12. R. Girometti, M. Bazzocchi, G. Como, G. Brondani, M. Del Pin, and B. Frea et al. Negative predictive value for cancer in patients with "Gray-Zone" PSA level and prior negative biopsy: preliminary results with multiparametric 3.0 tesla MR J Magn Reson Imaging 36 2012 943 950
13. T. Tamada, T. Sone, H. Higashi, Y. Jo, A. Yamamoto, and A. Kanki et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging AJR Am J Roentgenol 197 2011 664 670
14. J.C. Vilanova, C. Barcelo-Vidal, J. Comet, M. Boada, J. Barceló, and J. Ferrer et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer AJR Am J Roentgenol 196 2011 W715 W722
15. C.C. Ho, T.W. Khor, P. Singam, E.H. Goh, G.H. Tan, and B. Bahadzor et al. Evaluation of power Doppler ultrasonography for prostate biopsy in men with elevated serum prostate specific antigen levels Clin Ter 163 2012 211 214
16. P. Pepe, G. Candiano, M. Pennisi, and F. Aragona Can Sonovue targeted biopsy replace extended or saturation biopsy in prostate cancer diagnosis? Our experience at primary and repeat biopsy Arch Ital Urol Androl 82 2010 155 159
17. E. Kuligowska, M.A. Barish, H.M. Fenlon, and M. Blake Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers Radiology 220 2001 757 764
18. A. Stadlbauer, R. Bernt, E. Salomonowitz, E. Plas, G. Strunk, and K. Eberhardt [Health-economic evaluation of magnetic resonance imaging before biopsy for diagnosis of prostate cancer] Rofo 183 2011 925 932